Neurofibromatosis type 1 (NF1) is the most common of the three types of neurofibromatosis ... Most people with NF1 develop symptoms before age 10, though some symptoms may not appear until puberty.

Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

SpringWorks Therapeutics has announced the FDA approval of GOMEKLI (mirdametinib), the first medication for both adults and children aged 2 and older with neurofibromatosis type 1 (NF1 ...

Adam Pearson used his neurofibromatosis struggles to succeed in acting and advocacy, inspiring others to accept differences ...

Universiti Kebangsaan Malaysia (UKM) Neurosurgeon Prof Kamalanathan Palaniandy explains that Neurofibromatosis type 1 (NF1 ... What are the symptoms of NF1? Among the common signs of the condition ...

The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...

A Cuban woman staged a solitary protest outside the "Juan Manuel Márquez" Pediatric Hospital in Havana, demanding medical care for 10-year-old Damir ...

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat neurofibromatosis type 1 (NF1), a rare genetic disorder affecting approximately 100,000 ...

Genetic testing for people with type of NF, while possible, can be more complex than for individuals who do not have this form of the disorder. In cases where a child’s NF1 is determined to be the ...

The kinase inhibitor is now approved for adults and children aged ≥ 2 years with neurofibromatosis type 1 who have unresectable symptomatic plexiform neurofibromas.